It is a sad day when the company leading the way to use embryonic stem cells in the clinic must abdicate this role. Despite all they have achieved, which will undoubtedly benefit the field in the near future, I would guess that the tremendous amounts spent to date plus the need for continued development, plus the non-pharma business model increasingly caused their board nervousness culminating in shutting down the program. I wonder what Steve Jobs would say...